IKZF1 is altered in 1.64% of acute myeloid leukemia patients with IKZF1 Loss present in 0.38% of all acute myeloid leukemia patients [4].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and acute lymphoblastic leukemia as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 is altered in 2.86% of anaplastic large cell lymphoma patients [4].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for anaplastic large cell lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for Burkitt lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and Burkitt lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [4].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for chronic myeloid leukemia, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and chronic myeloid leukemia as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 is altered in 1.25% of follicular lymphoma patients [4].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for follicular lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and follicular lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and mantle cell lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for marginal zone lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and marginal zone lymphoma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 is altered in 0.48% of multiple myeloma patients [4].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and multiple myeloma as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 is altered in 0.45% of myelodysplastic syndromes patients [4].

IKZF1 Loss is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 Loss and myelodysplastic syndromes as inclusion criteria, 3 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IKZF1 Loss and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IKZF1 is altered in 1.82% of hodgkin lymphoma patients [4].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 Loss and hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for lymphoblastic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 Loss and lymphoblastic lymphoma as inclusion criteria, 2 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 Loss and myelofibrosis as inclusion criteria, 2 are phase 2 (1 open) [5].

IKZF1 is altered in 0.26% of myeloproliferative neoplasm patients [4].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for myeloproliferative neoplasm, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 Loss and myeloproliferative neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for plasma cell leukemia, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 Loss and plasma cell leukemia as inclusion criteria, 2 are phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 2 clinical trials for prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 Loss and prolymphocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [5].

IKZF1 is altered in 1.65% of acute leukemia patients with IKZF1 Loss present in 0.37% of all acute leukemia patients [4].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains IKZF1 Loss and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

IKZF1 is altered in 1.44% of mature T-cell and NK-cell neoplasm patients [4].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains IKZF1 Loss and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [5].

IKZF1 is altered in 0.9% of myelodysplastic syndrome with excess blasts-2 patients [4].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [5].

IKZF1 is altered in 2.27% of non-hodgkin lymphoma patients [4].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IKZF1 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (0 open) [5].

IKZF1 is altered in 1.23% of T-cell and NK-cell neoplasm patients [4].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

IKZF1 Loss is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 Loss and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [5].